BLACK DIAMOND THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$713.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-05
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.87M, a 58.35% increase year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.59M.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $582.00K.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was -$1.46M, a 226.97% decline year-over-year.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was -$1.41M.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$756.00K, a 119.20% decline from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $3.94M.
- BLACK DIAMOND THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was -$5.86M, a 167.29% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$713.00K 10-Q · filed 2026-08-05 | -$131.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.59M 10-Q · filed 2026-05-07 | -$3.00M derived: sum of 2 quarters · filed 2026-05-07 | -$4.47M derived: sum of 3 quarters · filed 2026-05-07 | -$2.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $582.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$882.00K derived: sum of 2 quarters · filed 2026-03-16 | $933.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.41M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $351.00K derived: sum of 2 quarters · filed 2026-08-05 | -$2.00M 10-Q · filed 2025-11-06 | -$4.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$532.00K 10-Q · filed 2026-08-05 | -$2.79M derived: sum of 3 quarters · filed 2026-08-05 | -$1.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$2.35M 10-Q · filed 2026-05-07 | -$4.61M derived: sum of 2 quarters · filed 2026-05-07 | -$3.46M derived: sum of 3 quarters · filed 2026-05-07 | -$1.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$2.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$1.11M derived: sum of 2 quarters · filed 2026-03-16 | $888.00K derived: sum of 3 quarters · filed 2026-03-16 | -$756.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.15M derived: sum of 2 quarters · filed 2025-11-06 | $1.51M 10-Q · filed 2025-11-06 | $4.46M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $354.00K 10-Q · filed 2025-08-07 | $3.30M derived: sum of 3 quarters · filed 2025-08-07 | $6.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$1.64M 10-Q · filed 2025-05-12 | $1.31M derived: sum of 2 quarters · filed 2025-05-12 | $4.52M derived: sum of 3 quarters · filed 2025-05-12 | $5.88M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $6.16M derived: sum of 2 quarters · filed 2025-03-06 | $7.52M derived: sum of 3 quarters · filed 2025-03-06 | $3.94M 10-K · filed 2025-03-06 |
| 2023-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $4.57M derived: sum of 2 quarters · filed 2024-11-05 | $988.00K 10-Q · filed 2024-11-05 | -$947.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$2.22M 10-Q · filed 2024-08-06 | -$4.16M derived: sum of 3 quarters · filed 2024-08-06 | -$6.25M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$3.58M 10-Q · filed 2024-05-09 | -$5.52M derived: sum of 2 quarters · filed 2024-05-09 | -$7.61M derived: sum of 3 quarters · filed 2024-05-09 | -$7.49M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$4.03M derived: sum of 2 quarters · filed 2024-03-12 | -$3.91M derived: sum of 3 quarters · filed 2024-03-12 | -$5.86M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$1.97M derived: sum of 2 quarters · filed 2023-11-06 | -$3.93M 10-Q · filed 2023-11-06 | -$5.91M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $122.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.84M 10-Q · filed 2023-08-11 | -$3.81M derived: sum of 3 quarters · filed 2023-08-11 | -$477.00K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$1.96M 10-Q · filed 2023-05-09 | -$3.94M derived: sum of 2 quarters · filed 2023-05-09 | -$599.00K derived: sum of 3 quarters · filed 2023-05-09 | $3.92M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $1.36M derived: sum of 2 quarters · filed 2023-03-09 | $5.88M derived: sum of 3 quarters · filed 2023-03-09 | $8.71M 10-K · filed 2023-03-09 |
| 2021-09-30 | $3.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $7.86M derived: sum of 2 quarters · filed 2022-11-08 | $10.69M 10-Q · filed 2022-11-08 | $14.17M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $4.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $7.36M 10-Q · filed 2022-08-09 | $10.83M derived: sum of 3 quarters · filed 2022-08-09 | $12.39M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.84M 10-Q · filed 2022-05-11 | $6.31M derived: sum of 2 quarters · filed 2022-05-11 | $7.87M derived: sum of 3 quarters · filed 2022-05-11 | $11.41M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $5.03M derived: sum of 2 quarters · filed 2022-03-17 | $8.57M derived: sum of 3 quarters · filed 2022-03-17 | $8.03M 10-K · filed 2022-03-17 |
| 2020-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $5.10M derived: sum of 2 quarters · filed 2021-11-08 | $4.55M 10-Q · filed 2021-11-08 | $5.48M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $3.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $2.99M 10-Q · filed 2021-08-12 | $3.92M derived: sum of 3 quarters · filed 2021-08-12 | $4.47M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$547.00K 10-Q · filed 2021-05-07 | $384.00K derived: sum of 2 quarters · filed 2021-05-07 | $931.00K derived: sum of 3 quarters · filed 2021-05-07 | $1.43M derived: sum of 4 quarters · filed 2021-05-07 |
| 2019-12-31 | $931.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $1.48M derived: sum of 2 quarters · filed 2021-03-25 | $1.97M derived: sum of 3 quarters · filed 2021-03-25 | $1.79M 10-K · filed 2021-03-25 |
| 2019-09-30 | $547.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $1.04M derived: sum of 2 quarters · filed 2020-11-10 | $860.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $494.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $313.00K 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | -$181.00K 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $294.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |